Case Study

DecisionDx Squamous Cell Carcinoma

Could this patient benefit from lower intensity treatment?

A 74-year-old caucasian male presents with two NCCN high risk factors.

Case details

The patient's lesion was a 2.2cm x 2.2cm primary cutaneous squamous cell carcinoma (cSCC) on the left posterior scalp. The patient required three stages of Mohs surgery and no additional high-risk pathological features were observed. The final post-surgical defect size was 4.2 cm x 4.2 cm with a defect depth to adipose tissue. 

  • CT scan
  • Radiation
  • Monthly follow-up

Why DecisionDx-SCC?

Due to the patient’s age, the clinician hoped to avoid radiation treatment. As well, the clinician was concerned with multiple cellular abnormalities, along with a depth within the adipose tissue, albeit not a depth beyond subcutaneous tissue. The clinician’s concerns were further compounded with the patient having two NCCN high risk factors, and the DecisionDx-SCC GEP test was ordered to help inform the level of post-surgical care required.

Test result

In this patient, the DecisionDx-SCC test result of Class 1 indicates a low biological risk for metastasis (7.4%). This assisted the clinician in deciding to forgo radiation and proceed with a lower intensity-level of treatment. One year post-treatment the wound healed and there was no sign of the disease present.

In light of the Class 1 DecisionDx-SCC test result, and the indication of a low risk of metastasis, the clinician determined that a lower intensity level of post-surgical management and surveillance would be more appropriate for the patient. Radiation treatment was deemed unnecessary and removed from the patient’s care plan. Follow-up was scheduled for monthly wound check, and nodal exams were scheduled for every 6 months. One-year post-treatment, the wound had healed with no evidence of recurrence or metastasis.

DecisionDx-SCC testing provided valuable objective information to the dermatologist and helped determine a lower intensity level of post-surgical management and surveillance would be more appropriate for the patient.

 This case study was published by Singh et al. Clinical, Cosmetic and Investigational Dermatology 2023 
1. Wysong et al. Late breaking presentation at AAD 2023; Data on file, Castle Biosciences